Revision Index

0
====================================================================================================
Revision URL

https://en.wikipedia.org/w/index.php?title=CRISPR gene editing&oldid=883727671
====================================================================================================
Revision Section Tree

{'name': 'root',
 'level': 0,
 'parent': None,
 'path': 'root',
 'text': 'A simple version of the CRISPR/Cas system, CRISPR/Cas9, has been modified to edit genomes. By delivering the Cas9 nuclease complexed with a synthetic guide RNA (gRNA) into a cell, the '
         "cell's genome can be cut at a desired location, allowing existing genes to be removed and/or new ones added.[2][3][4] The Cas9-gRNA complex corresponds with the CAS III CRISPR-RNA complex "
         'in the accompanying diagram.\n'
         '\n'
         'CRISPR/Cas genome editing techniques have many potential applications, including medicine and crop seed enhancement. The use of CRISPR/Cas9-gRNA complex for genome editing[5][6] was the '
         "AAAS's choice for breakthrough of the year in 2015.[7] Bioethical concerns have been raised about the prospect of using CRISPR for germline editing.[8]\n"
         '\n'
         '1 Predecessors\n'
         '\n'
         '2 Genome engineering2.1 Major components2.2 Structure2.3 Delivery2.4 Editing2.5 Controlled genome editing\n'
         '\n'
         '2.1 Major components\n'
         '\n'
         '2.2 Structure\n'
         '\n'
         '2.3 Delivery\n'
         '\n'
         '2.4 Editing\n'
         '\n'
         '2.5 Controlled genome editing\n'
         '\n'
         '3 Other applications3.1 Knockdown/activation3.2 RNA editing3.3 Disease models3.4 Gene drive3.5 Biomedicine3.5.1 CRISPR in cancer3.6 Gene function3.7 In vitro genetic depletion3.8 In vivo '
         'applications\n'
         '\n'
         '3.1 Knockdown/activation\n'
         '\n'
         '3.2 RNA editing\n'
         '\n'
         '3.3 Disease models\n'
         '\n'
         '3.4 Gene drive\n'
         '\n'
         '3.5 Biomedicine3.5.1 CRISPR in cancer\n'
         '\n'
         '3.5.1 CRISPR in cancer\n'
         '\n'
         '3.6 Gene function\n'
         '\n'
         '3.7 In vitro genetic depletion\n'
         '\n'
         '3.8 In vivo applications\n'
         '\n'
         '4 Patents and commercialization\n'
         '\n'
         '5 Society and culture5.1 Human germline modification5.2 Policy barriers to genetic engineering5.3 Recognition\n'
         '\n'
         '5.1 Human germline modification\n'
         '\n'
         '5.2 Policy barriers to genetic engineering\n'
         '\n'
         '5.3 Recognition\n'
         '\n'
         '6 References',
 'subsections': [{'name': 'Predecessors',
                  'level': 1,
                  'parent': 'root',
                  'path': 'root|Predecessors',
                  'text': 'In the early 2000s, researchers developed zinc finger nucleases (ZFNs), synthetic proteins whose DNA-binding domains enable them to create double-stranded breaks in DNA at '
                          'specific points. In 2010, synthetic nucleases called transcription activator-like effector nucleases (TALENs) provided an easier way to target a double-stranded break to a '
                          'specific location on the DNA strand. Both zinc finger nucleases and TALENs require the creation of a custom protein for each targeted DNA sequence, which is a more '
                          'difficult and time-consuming process than that for guide RNAs. CRISPRs are much easier to design because the process requires making only a short RNA sequence.[9]\n'
                          '\n'
                          'Whereas RNA interference (RNAi) does not fully suppress gene function, CRISPR, ZFNs and TALENs provide full irreversible gene knockout.[10] CRISPR can also target several '
                          'DNA sites simultaneously by simply introducing different gRNAs. In addition, CRISPR costs are relatively low.[10][11][12]',
                  'subsections': []},
                 {'name': 'Genome engineering',
                  'level': 1,
                  'parent': 'root',
                  'path': 'root|Genome engineering',
                  'text': 'CRISPR/Cas9 genome editing is carried out with a Type II CRISPR system. When utilized for genome editing, this system includes Cas9, crRNA, tracrRNA along with an optional '
                          'section of DNA repair template that is utilized in either non-homologous end joining (NHEJ) or homology directed repair (HDR).',
                  'subsections': [{'name': 'Major components',
                                   'level': 2,
                                   'parent': 'Genome engineering',
                                   'path': 'root|Genome engineering|Major components',
                                   'text': 'CRISPR/Cas9 often employs a plasmid to transfect the target cells.[15] The main components of this plasmid are displayed in the image and listed in the '
                                           "table. The crRNA needs to be designed for each application as this is the sequence that Cas9 uses to identify and directly bind to the cell's DNA. The "
                                           'crRNA must bind only where editing is desired. The repair template is designed for each application, as it must overlap with the sequences on either side '
                                           'of the cut and code for the insertion sequence.\n'
                                           '\n'
                                           'Multiple crRNAs and the tracrRNA can be packaged together to form a single-guide RNA (sgRNA).[16] This sgRNA can be joined together with the Cas9 gene and '
                                           'made into a plasmid in order to be transfected into cells.',
                                   'subsections': []},
                                  {'name': 'Structure',
                                   'level': 2,
                                   'parent': 'Genome engineering',
                                   'path': 'root|Genome engineering|Structure',
                                   'text': 'CRISPR/Cas9 offers a high degree of fidelity and relatively simple construction. It depends on two factors for its specificity: the target sequence and '
                                           'the PAM. The target sequence is 20 bases long as part of each CRISPR locus in the crRNA array.[15] A typical crRNA array has multiple unique target '
                                           "sequences. Cas9 proteins select the correct location on the host's genome by utilizing the sequence to bond with base pairs on the host DNA. The sequence "
                                           'is not part of the Cas9 protein and as a result is customizable and can be independently synthesized.[17][18]\n'
                                           '\n'
                                           'The PAM sequence on the host genome is recognized by Cas9. Cas9 cannot be easily modified to recognize a different PAM sequence. However this is not too '
                                           "limiting as it is a short sequence and nonspecific (e.g. the SpCas9 PAM sequence is 5'-NGG-3' and in the human genome occurs roughly every 8 to 12 base "
                                           'pairs).[15]\n'
                                           '\n'
                                           'Once these have been assembled into a plasmid and transfected into cells the Cas9 protein with the help of the crRNA finds the correct sequence in the '
                                           "host cell's DNA and – depending on the Cas9 variant – creates a single or double strand break in the DNA.[19]\n"
                                           '\n'
                                           'Properly spaced single strand breaks in the host DNA can trigger homology directed repair, which is less error prone than the non-homologous end joining '
                                           'that typically follows a double strand break. Providing a DNA repair template allows for the insertion of a specific DNA sequence at an exact location '
                                           "within the genome. The repair template should extend 40 to 90 base pairs beyond the Cas9 induced DNA break.[15] The goal is for the cell's HDR process to "
                                           'utilize the provided repair template and thereby incorporate the new sequence into the genome. Once incorporated, this new sequence is now part of the '
                                           "cell's genetic material and passes into its daughter cells.\n"
                                           '\n'
                                           'Many online tools are available to aid in designing effective sgRNA sequences.[20]',
                                   'subsections': []},
                                  {'name': 'Delivery',
                                   'level': 2,
                                   'parent': 'Genome engineering',
                                   'path': 'root|Genome engineering|Delivery',
                                   'text': 'Delivery of Cas9, sgRNA, and associated complexes into cells can occur via viral and non-viral systems. Electroporation of DNA, RNA, or '
                                           'ribonucleocomplexes is a common technique, though it can result in harmful effects on the target cells.[21] Chemical transfection techniques utilizing '
                                           'lipids have also been used to introduce sgRNA in complex with Cas9 into cells.[22] Hard-to-transfect cells (e.g. stem cells, neurons, and hematopoietic '
                                           'cells) require more efficient delivery systems such as those based on lentivirus (LVs), adenovirus (AdV) and adeno-associated virus (AAV).[23][24]',
                                   'subsections': []},
                                  {'name': 'Editing',
                                   'level': 2,
                                   'parent': 'Genome engineering',
                                   'path': 'root|Genome engineering|Editing',
                                   'text': 'CRISPRs have been used to cut five[25] to 62 genes at once: pig cells have been engineered to inactivate all 62 Porcine Endogenous Retroviruses in the pig '
                                           "genome, which eliminated transinfection from the pig to human cells in culture.[26] CRISPR's low cost compared to alternatives is widely seen as "
                                           'revolutionary.[2][3]\n'
                                           '\n'
                                           'Selective engineered redirection of the CRISPR/Cas system was first demonstrated in 2012 in:[27][28]\n'
                                           '\n'
                                           'Immunization of industrially important bacteria, including some used in food production and large-scale fermentation\n'
                                           '\n'
                                           'Cellular or organism RNA-guided genome engineering. Proof of concept studies demonstrated examples both in vitro[4][29][30] and in vivo[31][32][33]',
                                   'subsections': []},
                                  {'name': 'Controlled genome editing',
                                   'level': 2,
                                   'parent': 'Genome engineering',
                                   'path': 'root|Genome engineering|Controlled genome editing',
                                   'text': 'Several variants of CRISPR/Cas9 allow gene activation or genome editing with an external trigger such as light or small molecules.[34][35][36] These '
                                           'include photoactivatable CRISPR systems developed by fusing light-responsive protein partners with an activator domain and a dCas9 for gene '
                                           'activation,[37][38] or fusing similar light responsive domains with two constructs of split-Cas9,[39][40] or by incorporating caged unnatural amino acids '
                                           'into Cas9,[41] or by modifying the guide RNAs with photocleavable complements for genome editing.[42]\n'
                                           '\n'
                                           'Methods to control genome editing with small molecules include an allosteric Cas9, with no detectable background editing, that will activate binding and '
                                           'cleavage upon the addition of 4-hydroxytamoxifen (4-HT),[34] 4-HT responsive intein-linked Cas9s[43] or a Cas9 that is 4-HT responsive when fused to four '
                                           'ERT2 domains.[44] Intein-inducible split-Cas9 allows dimerization of Cas9 fragments[45] and Rapamycin-inducible split-Cas9 system developed by fusing two '
                                           'constructs of split Cas9 with FRB and FKBP fragments.[46] Furthermore, other studies have shown to induce transcription of Cas9 with a small molecule, '
                                           'doxycycline.[47][48] Small molecules can also be used to improve Homology Directed Repair (HDR),[49] often by inhibiting the Non-Homologous End Joining '
                                           '(NHEJ) pathway.[50] These systems allow conditional control of CRISPR activity for improved precision, efficiency and spatiotemporal control.',
                                   'subsections': []}]},
                 {'name': 'Other applications',
                  'level': 1,
                  'parent': 'root',
                  'path': 'root|Other applications',
                  'text': '',
                  'subsections': [{'name': 'Knockdown/activation',
                                   'level': 2,
                                   'parent': 'Other applications',
                                   'path': 'root|Other applications|Knockdown/activation',
                                   'text': 'Using "dead" versions of Cas9 (dCas9) eliminates CRISPR\'s DNA-cutting ability, while preserving its ability to target desirable sequences. Multiple '
                                           'groups added various regulatory factors to dCas9s, enabling them to turn almost any gene on or off or adjust its level of activity.[52] Like RNAi, CRISPR '
                                           'interference (CRISPRi) turns off genes in a reversible fashion by targeting, but not cutting a site. The targeted site is methylated, epigenetically '
                                           'modifying the gene. This modification inhibits transcription. These precisely placed modifications may then be used to regulate the effects on gene '
                                           'expressions and DNA dynamics after the inhibition of certain genome sequences within DNA. Within the past few years, epigenetic marks in different human '
                                           'cells have been closely researched and certain patterns within the marks have been found to correlate with everything ranging from tumor growth to brain '
                                           'activity.[53] Conversely, CRISPR-mediated activation (CRISPRa) promotes gene transcription.[54] Cas9 is an effective way of targeting and silencing '
                                           'specific genes at the DNA level.[55] In bacteria, the presence of Cas9 alone is enough to block transcription. For mammalian applications, a section of '
                                           'protein is added. Its guide RNA targets regulatory DNA sequences called promoters that immediately precede the target gene.[25]\n'
                                           '\n'
                                           'Cas9 was used to carry synthetic transcription factors that activated specific human genes. The technique achieved a strong effect by targeting multiple '
                                           "CRISPR constructs to slightly different locations on the gene's promoter.[25]",
                                   'subsections': []},
                                  {'name': 'RNA editing',
                                   'level': 2,
                                   'parent': 'Other applications',
                                   'path': 'root|Other applications|RNA editing',
                                   'text': 'In 2016, researchers demonstrated that CRISPR from an ordinary mouth bacterium could be used to edit RNA. The researchers searched databases containing '
                                           'hundreds of millions of genetic sequences for those that resembled Crispr genes. They considered the fusobacteria Leptotrichia shahii. It had a group of '
                                           'genes that resembled CRISPR genes, but with important differences. When the researchers equipped other bacteria with these genes, which they called C2c2, '
                                           'they found that the organisms gained a novel defense.[56]\n'
                                           '\n'
                                           'Many viruses encode their genetic information in RNA rather than DNA that they repurpose to make new viruses. HIV and poliovirus are such viruses. '
                                           'Bacteria with C2c2 make molecules that can dismember RNA, destroying the virus. Tailoring these genes opened any RNA molecule to editing.[56]\n'
                                           '\n'
                                           'CRISPR-Cas systems can also be employed for editing of micro-RNA and long-noncoding RNA genes in plants.[57]',
                                   'subsections': []},
                                  {'name': 'Disease models',
                                   'level': 2,
                                   'parent': 'Other applications',
                                   'path': 'root|Other applications|Disease models',
                                   'text': 'CRISPR simplifies creation of animals for research that mimic disease or show what happens when a gene is knocked down or mutated. CRISPR may be used at '
                                           'the germline level to create animals where the gene is changed everywhere, or it may be targeted at non-germline cells.[58][59][60]\n'
                                           '\n'
                                           'CRISPR can be utilized to create human cellular models of disease. For instance, applied to human pluripotent stem cells CRISPR introduced targeted '
                                           'mutations in genes relevant to polycystic kidney disease (PKD) and focal segmental glomerulosclerosis (FSGS).[61] These CRISPR-modified pluripotent stem '
                                           'cells were subsequently grown into human kidney organoids that exhibited disease-specific phenotypes. Kidney organoids from stem cells with PKD mutations '
                                           'formed large, translucent cyst structures from kidney tubules. The cysts were capable of reaching macroscopic dimensions, up to one centimeter in '
                                           'diameter.[62] Kidney organoids with mutations in a gene linked to FSGS developed junctional defects between podocytes, the filtering cells affected in '
                                           'that disease. This was traced to the inability of podocytes ability to form microvilli between adjacent cells.[63] Importantly, these disease phenotypes '
                                           'were absent in control organoids of identical genetic background, but lacking the CRISPR modifications.[61]\n'
                                           '\n'
                                           'A similar approach was taken to model long QT syndrome in cardiomyocytes derived from pluripotent stem cells.[64] These CRISPR-generated cellular models, '
                                           'with isogenic controls, provide a new way to study human disease and test drugs.',
                                   'subsections': []},
                                  {'name': 'Gene drive',
                                   'level': 2,
                                   'parent': 'Other applications',
                                   'path': 'root|Other applications|Gene drive',
                                   'text': 'Gene drives may provide a powerful tool to restore balance of ecosystems by eliminating invasive species. Concerns regarding efficacy, unintended '
                                           'consequences in the target species as well as non-target species have been raised particularly in the potential for accidental release from laboratories '
                                           'into the wild. Scientists have proposed several safeguards for ensuring the containment of experimental gene drives including molecular, reproductive, and '
                                           'ecological.[65] Many recommend that immunization and reversal drives be developed in tandem with gene drives in order to overwrite their effects if '
                                           'necessary.[66] There remains consensus that long-term effects must be studied more thoroughly particularly in the potential for ecological disruption that '
                                           'cannot be corrected with reversal drives.[67]',
                                   'subsections': []},
                                  {'name': 'Biomedicine',
                                   'level': 2,
                                   'parent': 'Other applications',
                                   'path': 'root|Other applications|Biomedicine',
                                   'text': 'CRISPR/Cas technology has been proposed as a treatment for multiple human diseases, especially those with a genetic cause.[68] Its ability to modify '
                                           'specific DNA sequences makes it a tool with potential to fix disease-causing mutations. Early research in animal models suggest that therapies based on '
                                           'CRISPR technology have potential to treat a wide range of diseases,[69] including cancer,[70][71] beta-thalassemia,[72] sickle cell disease,[73] '
                                           "hemophilia,[74] cystic fibrosis,[75] Duchenne's muscular dystrophy,[76] Huntington's,[77][78] and heart disease.[79]\n"
                                           '\n'
                                           'CRISPR/Cas-based "RNA-guided nucleases" can be used to target virulence factors, genes encoding antibiotic resistance and other medically relevant '
                                           'sequences of interest. This technology thus represents a novel form of antimicrobial therapy and a strategy by which to manipulate bacterial '
                                           'populations.[80][81] Recent studies suggested a correlation between the interfering of the CRISPR/Cas locus and acquisition of antibiotic resistance[82] '
                                           'This system provides protection of bacteria against invading foreign DNA, such as transposons, bacteriophages and plasmids. This system was shown to be a '
                                           'strong selective pressure for the acquisition of antibiotic resistance and virulence factor in bacterial pathogens.[82] Some of the affected genes are '
                                           'tied to human diseases, including those involved in muscle differentiation, cancer, inflammation and fetal hemoglobin.[25]\n'
                                           '\n'
                                           'Research suggests that CRISPR is an effective way to limit replication of multiple herpesviruses. It was able to eradicate viral DNA in the case of '
                                           'Epstein-Barr virus (EBV). Anti-herpesvirus CRISPRs have promising applications such as removing cancer-causing EBV from tumor cells, helping rid donated '
                                           'organs for immunocompromised patients of viral invaders, or preventing cold sore outbreaks and recurrent eye infections by blocking HSV-1 reactivation. As '
                                           'of August\xa02016[update], these were awaiting testing.[83] CRISPR is being applied to develop tissue-based treatments for cancer and other '
                                           'diseases.[52][84]\n'
                                           '\n'
                                           'CRISPR may revive the concept of transplanting animal organs into people. Retroviruses present in animal genomes could harm transplant recipients. In '
                                           "2015, a team eliminated 62 copies of a retrovirus's DNA from the pig genome in a kidney epithelial cell.[52] Researchers recently demonstrated the ability "
                                           'to birth live pig specimens after removing these retroviruses from their genome using CRISPR for the first time.[85]\n'
                                           '\n'
                                           'CRISPR may have applications in tissue engineering and regenerative medicine, such as by creating human blood vessels that lack expression of MHC class II '
                                           'proteins, which often cause transplant rejection.[86]',
                                   'subsections': [{'name': 'CRISPR in cancer',
                                                    'level': 3,
                                                    'parent': 'Biomedicine',
                                                    'path': 'root|Other applications|Biomedicine|CRISPR in cancer',
                                                    'text': 'As of 2016[update] CRISPR had been studied in animal models and cancer cell lines, to learn if it can be used to repair or thwart mutated '
                                                            'genes that cause cancer.[87]\n'
                                                            '\n'
                                                            'The first clinical trial involving CRISPR started in 2016. It involved removing immune cells from people with lung cancer, using CRISPR '
                                                            'to edit out the gene expressed PD-1, then administrating the altered cells back to the same person. 20 other trials were under way or '
                                                            'nearly ready, mostly in China, as of 2017[update].[88]\n'
                                                            '\n'
                                                            'In 2016, the United States Food and Drug Administration (FDA) approved a clinical trial in which CRISPR would be used to alter T cells '
                                                            'extracted from people with different kinds of cancer and then administer those engineered T cells back to the same people.[89]\n'
                                                            '\n'
                                                            'In May 2018, the company CRISPR Therapeutics received approval to start a clinical trial with a CRISPR-based treatment for the blood '
                                                            'disorder beta-thalassemia, which is scheduled to start in late 2018.[90][91]',
                                                    'subsections': []}]},
                                  {'name': 'Gene function',
                                   'level': 2,
                                   'parent': 'Other applications',
                                   'path': 'root|Other applications|Gene function',
                                   'text': 'In 2015, multiple studies attempted to systematically disable each individual human gene, in an attempt to identify which genes were essential to human '
                                           'biology. Between 1,600 and 1,800 genes passed this test—of the 20,000 or so known human genes. Such genes are more strongly activated, and unlikely to '
                                           'carry disabling mutations. They are more likely to have indispensable counterparts in other species. They build proteins that unite to form larger '
                                           'collaborative complexes. The studies also cataloged the essential genes in four cancer-cell lines and identified genes that are expendable in healthy '
                                           'cells, but crucial in specific tumor types and drugs that could target these rogue genes.[92]\n'
                                           '\n'
                                           'The specific functions of some 18 percent of the essential genes are unidentified. In one 2015 targeting experiment, disabling individual genes in groups '
                                           'of cells attempted to identify those involved in resistance to a melanoma drug. Each such gene manipulation is itself a separate "drug", potentially '
                                           'opening the entire genome to CRISPR-based regulation.[52]',
                                   'subsections': []},
                                  {'name': 'In vitro genetic depletion',
                                   'level': 2,
                                   'parent': 'Other applications',
                                   'path': 'root|Other applications|In vitro genetic depletion',
                                   'text': 'Unenriched sequencing libraries often have abundant undesired sequences. Cas9 can specifically deplete the undesired sequences with double strand breakage '
                                           'with up to 99% efficiency and without significant off-target effects as seen with restriction enzymes. Treatment with Cas9 can deplete abundant rRNA while '
                                           'increasing pathogen sensitivity in RNA-seq libraries.[93]',
                                   'subsections': []},
                                  {'name': 'In vivo applications',
                                   'level': 2,
                                   'parent': 'Other applications',
                                   'path': 'root|Other applications|In vivo applications',
                                   'text': 'CRISPR/Cas-9 can be used to edit the DNA of organisms in vivo and entire chromosomes can be eliminated from an organism at any point in its development. '
                                           'Chromosomes that have been deleted in vivo are the Y chromosomes and X chromosomes of adult lab mice and human chromosomes 14 and 21, in embryonic stem '
                                           'cell lines and aneuploid mice respectively. This method might be useful for treating genetic aneuploid diseases such as Down Syndrome and intersex '
                                           'disorders.[94]\n'
                                           '\n'
                                           'Successful in vivo genome editing using CRISPR/Cas9 has been shown in several model organisms, such as Escherichia coli,[95] Saccharomyces cerevisiae,[96] '
                                           'Candida albicans,[97] Caenorhadbitis elegans,[98] Arabidopsis,[99] Danio rerio,[100] Mus musculus.[101][102] Successes have been achieved in the study of '
                                           'basic biology, in the creation of disease models,[98] and in the experimental treatment of disease models.[103]\n'
                                           '\n'
                                           'Concerns have been raised that off-target effects (editing of genes besides the ones intended) may obscure the results of a CRISPR gene editing experiment '
                                           '(the observed phenotypic change may not be due to modifying the target gene, but some other gene). Modifications to CRISPR have been made to minimize the '
                                           'possibility of off-target effects. In addition, orthogonal CRISPR experiments are recommended to confirm the results of a gene editing '
                                           'experiment.[104][105]',
                                   'subsections': []}]},
                 {'name': 'Patents and commercialization',
                  'level': 1,
                  'parent': 'root',
                  'path': 'root|Patents and commercialization',
                  'text': 'As of December\xa02014[update], patent rights to CRISPR were contested. Several companies formed to develop related drugs and research tools.[106] As companies ramp up '
                          'financing, doubts as to whether CRISPR can be quickly monetized were raised.[107] In February 2017 the US Patent Office ruled on a patent interference case brought by '
                          'University of California with respect to patents issued to the Broad Institute, and found that the Broad patents, with claims covering the application of CRISPR/cas9 in '
                          'eukaryotic cells, were distinct from the inventions claimed by University of California.[108][109][110]Shortly after, University of California filed an appeal of this '
                          'ruling.[111][112]\n'
                          '\n'
                          'As of November\xa02013[update], SAGE Labs (part of Horizon Discovery group) had exclusive rights from one of those companies to produce and sell genetically engineered '
                          'rats and non-exclusive rights for mouse and rabbit models.[113] By 2015[update], Thermo Fisher Scientific had licensed intellectual property from ToolGen to develop CRISPR '
                          'reagent kits.[114]\n'
                          '\n'
                          'In March 2017, the European Patent Office (EPO) announced its intention to allow broad claims for editing all kinds of cells to Max-Planck Institute in Berlin, University '
                          'of California, and University of Vienna,[115][116] and in August 2017, the EPO announced its intention to allow CRISPR claims in a patent application that MilliporeSigma '
                          'had filed.[115] As of August\xa02017[update] the patent situation in Europe was complex, with MilliporeSigma, ToolGen, Vilnius University, and Harvard contending for '
                          'claims, along with University of California and Broad.[117]\n'
                          '\n'
                          'As of November 2018, all the CRISPR patent holders and institutes associated with them have set up companies to commercialize the patents by sub-licensing them for '
                          'therapeutic, agriculture and many other application areas to biotech firms, pharmaceuticals, agri-businesses etc. Caribou Biosciences, ERS Genomics, Editas Medicine, '
                          'Intellia Therapeutics, and CRISPR Therapeutics are the spin offs associated with CRISPR landscape. Not many large scale commercial assignees have actively participated in '
                          'the early phases of the CRISPR–Cas patent landscape. The only large establishments making it to the top ten are Dow AgroSciences and DuPont Nutrition Science (now merged '
                          'as DowDuPont), together holding 20 inventions in CRISPR-Cas9 applications in agriculture and animal biotechnology[118].',
                  'subsections': []},
                 {'name': 'Society and culture',
                  'level': 1,
                  'parent': 'root',
                  'path': 'root|Society and culture',
                  'text': '',
                  'subsections': [{'name': 'Human germline modification',
                                   'level': 2,
                                   'parent': 'Society and culture',
                                   'path': 'root|Society and culture|Human germline modification',
                                   'text': 'As of March 2015, multiple groups had announced ongoing research to learn how they one day might apply CRISPR to human embryos, including labs in the US, '
                                           'China, and the UK, as well as US biotechnology company OvaScience.[119] Scientists, including a CRISPR co-discoverer, urged a worldwide moratorium on '
                                           'applying CRISPR to the human germline, especially for clinical use. They said "scientists should avoid even attempting, in lax jurisdictions, germline '
                                           'genome modification for clinical application in humans" until the full implications "are discussed among scientific and governmental '
                                           'organizations".[120][121] These scientists support further low-level research on CRISPR and do not see CRISPR as developed enough for any clinical use in '
                                           'making heritable changes to humans.[122]\n'
                                           '\n'
                                           'In April 2015, Chinese scientists reported results of an attempt to alter the DNA of non-viable human embryos using CRISPR to correct a mutation that '
                                           'causes beta thalassemia, a lethal heritable disorder.[123][124] The study had previously been rejected by both Nature and Science in part because of '
                                           'ethical concerns.[125] The experiments resulted in successfully changing only some of the intended genes, and had off-target effects on other genes. The '
                                           'researchers stated that CRISPR is not ready for clinical application in reproductive medicine.[125] In April 2016, Chinese scientists were reported to '
                                           'have made a second unsuccessful attempt to alter the DNA of non-viable human embryos using CRISPR - this time to alter the CCR5 gene to make the embryo '
                                           'HIV resistant.[126]\n'
                                           '\n'
                                           'In December 2015, an International Summit on Human Gene Editing took place in Washington under the guidance of David Baltimore. Members of national '
                                           'scientific academies of America, Britain and China discussed the ethics of germline modification. They agreed to support basic and clinical research under '
                                           'certain legal and ethical guidelines. A specific distinction was made between somatic cells, where the effects of edits are limited to a single '
                                           'individual, versus germline cells, where genome changes could be inherited by descendants. Heritable modifications could have unintended and far-reaching '
                                           'consequences for human evolution, genetically (e.g. gene/environment interactions) and culturally (e.g. Social Darwinism). Altering of gametocytes and '
                                           'embryos to generate inheritable changes in humans was defined to be irresponsible. The group agreed to initiate an international forum to address such '
                                           'concerns and harmonize regulations across countries.[127]\n'
                                           '\n'
                                           'In November 2018, Jiankui He announced that he had edited two human embryos, to attempt to disable the gene for CCR5, which codes for a receptor that HIV '
                                           'uses to enter cells. He said that twin girls, Lulu and Nana, had been born a few weeks earlier. He said that the girls still carried functional copies of '
                                           'CCR5 along with disabled CCR5 (mosaicism) and were still vulnerable to HIV. The work was widely condemned as unethical, dangerous, and premature.[128]',
                                   'subsections': []},
                                  {'name': 'Policy barriers to genetic engineering',
                                   'level': 2,
                                   'parent': 'Society and culture',
                                   'path': 'root|Society and culture|Policy barriers to genetic engineering',
                                   'text': 'Policy regulations for the CRISPR/cas9 system vary around the globe. In February 2016, British scientists were given permission by regulators to '
                                           'genetically modify human embryos by using CRISPR-Cas9 and related techniques. However, researchers were forbidden from implanting the embryos and the '
                                           'embryos were to be destroyed after seven days.[129]\n'
                                           '\n'
                                           'The US has an elaborate, interdepartmental regulatory system to evaluate new genetically modified foods and crops. For example, the Agriculture Risk '
                                           'Protection Act of 2000 gives the USDA the authority to oversee the detection, control, eradication, suppression, prevention, or retardation of the spread '
                                           'of plant pests or noxious weeds to protect the agriculture, environment and economy of the US. The act regulates any genetically modified organism that '
                                           'utilizes the genome of a predefined "plant pest" or any plant not previously categorized.[130] In 2015, Yinong Yang successfully deactivated 16 specific '
                                           'genes in the white button mushroom, to make them non-browning. Since he had not added any foreign-species (transgenic) DNA to his organism, the mushroom '
                                           "could not be regulated by the USDA under Section 340.2.[131] Yang's white button mushroom was the first organism genetically modified with the Crispr/cas9 "
                                           'protein system to pass US regulation.[132] In 2016, the USDA sponsored a committee to consider future regulatory policy for upcoming genetic modification '
                                           'techniques. With the help of the US National Academies of Sciences, Engineering and Medicine, special interests groups met on April 15 to contemplate the '
                                           'possible advancements in genetic engineering within the next five years and any new regulations that might be needed as a result.[133] The FDA in 2017 '
                                           'proposed a rule that would classify genetic engineering modifications to animals as "animal drugs", subjecting them to strict regulation if offered for '
                                           'sale, and reducing the ability for individuals and small businesses to make them profitably.[134][135]\n'
                                           '\n'
                                           'In China, where social conditions sharply contrast with the west, genetic diseases carry a heavy stigma.[136] This leaves China with fewer policy barriers '
                                           'to the use of this technology.[137][138]',
                                   'subsections': []},
                                  {'name': 'Recognition',
                                   'level': 2,
                                   'parent': 'Society and culture',
                                   'path': 'root|Society and culture|Recognition',
                                   'text': "In 2012, and 2013, CRISPR was a runner-up in Science Magazine's Breakthrough of the Year award. In 2015, it was the winner of that award.[52] CRISPR was "
                                           "named as one of MIT Technology Review's 10 breakthrough technologies in 2014 and 2016.[139][140] In 2016, Jennifer Doudna, Emmanuelle Charpentier, along "
                                           'with Rudolph Barrangou, Philippe Horvath, and Feng Zhang won the Gairdner International award. In 2017, Jennifer Doudna and Emmanuelle Charpentier were '
                                           'awarded the Japan Prize for their revolutionary invention of CRISPR-Cas9 in Tokyo, Japan. In 2016, Emmanuelle Charpentier, Jennifer Doudna, and Feng Zhang '
                                           'won the Tang Prize in Biopharmaceutical Science.[141]',
                                   'subsections': []}]},
                 {'name': 'References',
                  'level': 1,
                  'parent': 'root',
                  'path': 'root|References',
                  'text': '^ Cite error: The named reference pmid20056882 was invoked but never defined (see the help page).\n'
                          '\n'
                          '^ a b .mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\\"""\\"""\'""\'"}.mw-parser-output .id-lock-free a,.mw-parser-output '
                          '.citation .cs1-lock-free a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px '
                          'no-repeat}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation '
                          '.cs1-lock-registration a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px '
                          'no-repeat}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription '
                          'a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px '
                          'no-repeat}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration '
                          'span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon '
                          'a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px '
                          'no-repeat}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output '
                          '.cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output '
                          '.cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output '
                          '.cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation '
                          '.mw-selflink{font-weight:inherit}Ledford H (2015). "CRISPR, the disruptor". Nature. 522 (7554): 20–4. Bibcode:2015Natur.522...20L. doi:10.1038/522020a. PMID\xa026040877.\n'
                          '\n'
                          '^ a b Snyder B (21 August 2014). "New technique accelerates genome editing process". research news @ Vanderbilt. Nashville, Tennessee: Vanderbilt University.\n'
                          '\n'
                          '^ a b Hendel A, Bak RO, Clark JT, Kennedy AB, Ryan DE, Roy S, Steinfeld I, Lunstad BD, Kaiser RJ, Wilkens AB, Bacchetta R, Tsalenko A, Dellinger D, Bruhn L, Porteus MH '
                          '(September 2015). "Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells". Nature Biotechnology. 33 (9): 985–9. doi:10.1038/nbt.3290. '
                          'PMC\xa04729442. PMID\xa026121415.\n'
                          '\n'
                          '^ Ledford H (March 2016). "CRISPR: gene editing is just the beginning". Nature. 531 (7593): 156–9. Bibcode:2016Natur.531..156L. doi:10.1038/531156a. PMID\xa026961639.\n'
                          '\n'
                          '^ Maxmen A (August 2015). "The Genesis Engine". WIRED. Retrieved 2016-06-05.\n'
                          '\n'
                          '^ Travis J (17 December 2015). "Breakthrough of the Year: CRISPR makes the cut". Science Magazine. American Association for the Advancement of Science.\n'
                          '\n'
                          '^ Cite error: The named reference NatNews2015 was invoked but never defined (see the help page).\n'
                          '\n'
                          '^ Young S (11 February 2014). "CRISPR and Other Genome Editing Tools Boost Medical Research and Gene Therapy\'s Reach". MIT Technology Review. Retrieved 2014-04-13.\n'
                          '\n'
                          '^ a b Heidenreich M, Zhang F (January 2016). "Applications of CRISPR-Cas systems in neuroscience". Nature Reviews. Neuroscience. 17 (1): 36–44. doi:10.1038/nrn.2015.2. '
                          'PMC\xa04899966. PMID\xa026656253.\n'
                          '\n'
                          '^ Barrangou R, Doudna JA (September 2016). "Applications of CRISPR technologies in research and beyond". Nature Biotechnology. 34 (9): 933–941. doi:10.1038/nbt.3659. '
                          'PMID\xa027606440.\n'
                          '\n'
                          '^ Cox DB, Platt RJ, Zhang F (February 2015). "Therapeutic genome editing: prospects and challenges". Nature Medicine. 21 (2): 121–31. doi:10.1038/nm.3793. PMC\xa04492683. '
                          'PMID\xa025654603.\n'
                          '\n'
                          '^ "CRISPR/Cas9 Plasmids". www.systembio.com. Retrieved 2015-12-17.\n'
                          '\n'
                          '^ "CRISPR Cas9 Genome Editing". www.origene.com. OriGene. Retrieved 2015-12-17.\n'
                          '\n'
                          '^ a b c d e Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F (November 2013). "Genome engineering using the CRISPR-Cas9 system". Nature Protocols. 8 (11): 2281–308. '
                          'doi:10.1038/nprot.2013.143. hdl:1721.1/102943. PMC\xa03969860. PMID\xa024157548.\n'
                          '\n'
                          '^ Ly, Joseph (2013). Discovering Genes Responsible for Kidney Diseases (Ph.D.). University of Toronto. Retrieved 26 December 2016.\n'
                          '\n'
                          '^ Horvath P, Barrangou R (January 2010). "CRISPR/Cas, the immune system of bacteria and archaea". Science. 327 (5962): 167–70. Bibcode:2010Sci...327..167H. '
                          'doi:10.1126/science.1179555. PMID\xa020056882.\n'
                          '\n'
                          '^ Bialk P, Rivera-Torres N, Strouse B, Kmiec EB (2015-06-08). "Regulation of Gene Editing Activity Directed by Single-Stranded Oligonucleotides and CRISPR/Cas9 Systems". '
                          'PLOS One. 10 (6): e0129308. Bibcode:2015PLoSO..1029308B. doi:10.1371/journal.pone.0129308. PMC\xa04459703. PMID\xa026053390.\n'
                          '\n'
                          '^ Sanders R (12 November 2015). "CRISPR-Cas9 gene editing: check three times, cut once". University of California, Berkeley. Archived from the original on 26 December '
                          '2016. Retrieved 26 December 2016. Unknown parameter |deadurl= ignored (|url-status= suggested) (help)\n'
                          '\n'
                          '^ "Optimized CRISPR Design". crispr.mit.edu. Retrieved 2015-12-20.\n'
                          '\n'
                          '^ Lino CA, Harper JC, Carney JP, Timlin JA (November 2018). "Delivering CRISPR: a review of the challenges and approaches". Drug Delivery. 25 (1): 1234–1257. '
                          'doi:10.1080/10717544.2018.1474964. PMC\xa06058482. PMID\xa029801422.\n'
                          '\n'
                          '^ Li L, Hu S, Chen X (July 2018). "Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities". Biomaterials. 171: 207–218. '
                          'doi:10.1016/j.biomaterials.2018.04.031. PMC\xa05944364. PMID\xa029704747.\n'
                          '\n'
                          '^ Schmidt F, Grimm D (February 2015). "CRISPR genome engineering and viral gene delivery: a case of mutual attraction". Biotechnology Journal. 10 (2): 258–72. '
                          'doi:10.1002/biot.201400529. PMID\xa025663455.\n'
                          '\n'
                          '^ Waxmonsky N (24 September 2015). "CRISPR 101: Mammalian Expression Systems and Delivery Methods". Retrieved 11 June 2018.\n'
                          '\n'
                          '^ a b c d Cite error: The named reference craze was invoked but never defined (see the help page).\n'
                          '\n'
                          '^ Zimmerman C (Oct 15, 2015). "Editing of Pig DNA May Lead to More Organs for People". NY Times.\n'
                          '\n'
                          '^ Hale CR, Majumdar S, Elmore J, Pfister N, Compton M, Olson S, Resch AM, Glover CV, Graveley BR, Terns RM, Terns MP (February 2012). "Essential features and rational '
                          'design of CRISPR RNAs that function with the Cas RAMP module complex to cleave RNAs". Molecular Cell. 45 (3): 292–302. doi:10.1016/j.molcel.2011.10.023. PMC\xa03278580. '
                          'PMID\xa022227116.\n'
                          '\n'
                          '^ Sorek R, Kunin V, Hugenholtz P (March 2008). "CRISPR--a widespread system that provides acquired resistance against phages in bacteria and archaea". Nature Reviews. '
                          'Microbiology. 6 (3): 181–6. doi:10.1038/nrmicro1793. PMID\xa018157154.\n'
                          '\n'
                          '^ Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E (August 2012). "A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity". '
                          'Science. 337 (6096): 816–21. Bibcode:2012Sci...337..816J. doi:10.1126/science.1225829. PMID\xa022745249.\n'
                          '\n'
                          '^ Cite error: The named reference pmid22949671 was invoked but never defined (see the help page).\n'
                          '\n'
                          '^ Cite error: The named reference pmid23643243 was invoked but never defined (see the help page).\n'
                          '\n'
                          '^ Cite error: The named reference Cong2013 was invoked but never defined (see the help page).\n'
                          '\n'
                          '^ Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM (February 2013). "RNA-guided human genome engineering via Cas9". Science. 339 (6121): '
                          '823–6. Bibcode:2013Sci...339..823M. doi:10.1126/science.1232033. PMC\xa03712628. PMID\xa023287722.Hou Z, Zhang Y, Propson NE, Howden SE, Chu LF, Sontheimer EJ, Thomson JA '
                          '(September 2013). "Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis". Proceedings of the National Academy of Sciences of '
                          'the United States of America. 110 (39): 15644–9. Bibcode:2013PNAS..11015644H. doi:10.1073/pnas.1313587110. PMC\xa03785731. PMID\xa023940360.\n'
                          '\n'
                          '^ a b Oakes BL, Nadler DC, Flamholz A, Fellmann C, Staahl BT, Doudna JA, Savage DF (June 2016). "Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 '
                          'switch". Nature Biotechnology. 34 (6): 646–51. doi:10.1038/nbt.3528. PMC\xa04900928. PMID\xa027136077.\n'
                          '\n'
                          '^ Nuñez JK, Harrington LB, Doudna JA (March 2016). "Chemical and Biophysical Modulation of Cas9 for Tunable Genome Engineering". ACS Chemical Biology. 11 (3): 681–8. '
                          'doi:10.1021/acschembio.5b01019. PMID\xa026857072.\n'
                          '\n'
                          '^ Zhou W, Deiters A (April 2016). "Conditional Control of CRISPR/Cas9 Function". Angewandte Chemie. 55 (18): 5394–9. doi:10.1002/anie.201511441. PMID\xa026996256.\n'
                          '\n'
                          '^ Polstein LR, Gersbach CA (March 2015). "A light-inducible CRISPR-Cas9 system for control of endogenous gene activation". Nature Chemical Biology. 11 (3): 198–200. '
                          'doi:10.1038/nchembio.1753. PMC\xa04412021. PMID\xa025664691.\n'
                          '\n'
                          '^ Nihongaki Y, Yamamoto S, Kawano F, Suzuki H, Sato M (February 2015). "CRISPR-Cas9-based photoactivatable transcription system". Chemistry & Biology. 22 (2): 169–74. '
                          'doi:10.1016/j.chembiol.2014.12.011. PMID\xa025619936.\n'
                          '\n'
                          '^ Wright AV, Sternberg SH, Taylor DW, Staahl BT, Bardales JA, Kornfeld JE, Doudna JA (March 2015). "Rational design of a split-Cas9 enzyme complex". Proceedings of the '
                          'National Academy of Sciences of the United States of America. 112 (10): 2984–9. Bibcode:2015PNAS..112.2984W. doi:10.1073/pnas.1501698112. PMC\xa04364227. PMID\xa0'
                          '25713377.\n'
                          '\n'
                          '^ Nihongaki Y, Kawano F, Nakajima T, Sato M (July 2015). "Photoactivatable CRISPR-Cas9 for optogenetic genome editing". Nature Biotechnology. 33 (7): 755–60. '
                          'doi:10.1038/nbt.3245. PMID\xa026076431.\n'
                          '\n'
                          '^ Hemphill J, Borchardt EK, Brown K, Asokan A, Deiters A (May 2015). "Optical Control of CRISPR/Cas9 Gene Editing". Journal of the American Chemical Society. 137 (17): '
                          '5642–5. doi:10.1021/ja512664v. PMC\xa04919123. PMID\xa025905628.\n'
                          '\n'
                          '^ Jain PK, Ramanan V, Schepers AG, Dalvie NS, Panda A, Fleming HE, Bhatia SN (September 2016). "Development of Light-Activated CRISPR Using Guide RNAs with Photocleavable '
                          'Protectors". Angewandte Chemie. 55 (40): 12440–4. doi:10.1002/anie.201606123. PMC\xa05864249. PMID\xa027554600.\n'
                          '\n'
                          '^ Davis KM, Pattanayak V, Thompson DB, Zuris JA, Liu DR (May 2015). "Small molecule-triggered Cas9 protein with improved genome-editing specificity". Nature Chemical '
                          'Biology. 11 (5): 316–8. doi:10.1038/nchembio.1793. PMC\xa04402137. PMID\xa025848930.\n'
                          '\n'
                          '^ Liu KI, Ramli MN, Woo CW, Wang Y, Zhao T, Zhang X, Yim GR, Chong BY, Gowher A, Chua MZ, Jung J, Lee JH, Tan MH (November 2016). "A chemical-inducible CRISPR-Cas9 system '
                          'for rapid control of genome editing". Nature Chemical Biology. 12 (11): 980–987. doi:10.1038/nchembio.2179. PMID\xa027618190.\n'
                          '\n'
                          '^ Truong DJ, Kühner K, Kühn R, Werfel S, Engelhardt S, Wurst W, Ortiz O (July 2015). "Development of an intein-mediated split-Cas9 system for gene therapy". Nucleic Acids '
                          'Research. 43 (13): 6450–8. doi:10.1093/nar/gkv601. PMC\xa04513872. PMID\xa026082496.\n'
                          '\n'
                          '^ Zetsche B, Volz SE, Zhang F (February 2015). "A split-Cas9 architecture for inducible genome editing and transcription modulation". Nature Biotechnology. 33 (2): 139–42. '
                          'doi:10.1038/nbt.3149. PMC\xa04503468. PMID\xa025643054.\n'
                          '\n'
                          '^ González F, Zhu Z, Shi ZD, Lelli K, Verma N, Li QV, Huangfu D (August 2014). "An iCRISPR platform for rapid, multiplexable, and inducible genome editing in human '
                          'pluripotent stem cells". Cell Stem Cell. 15 (2): 215–26. doi:10.1016/j.stem.2014.05.018. PMC\xa04127112. PMID\xa024931489.\n'
                          '\n'
                          '^ Dow LE, Fisher J, O\'Rourke KP, Muley A, Kastenhuber ER, Livshits G, Tschaharganeh DF, Socci ND, Lowe SW (April 2015). "Inducible in vivo genome editing with '
                          'CRISPR-Cas9". Nature Biotechnology. 33 (4): 390–4. doi:10.1038/nbt.3155. PMC\xa04390466. PMID\xa025690852.\n'
                          '\n'
                          '^ Yu C, Liu Y, Ma T, Liu K, Xu S, Zhang Y, Liu H, La Russa M, Xie M, Ding S, Qi LS (February 2015). "Small molecules enhance CRISPR genome editing in pluripotent stem '
                          'cells". Cell Stem Cell. 16 (2): 142–7. doi:10.1016/j.stem.2015.01.003. PMC\xa04461869. PMID\xa025658371.\n'
                          '\n'
                          '^ Maruyama T, Dougan SK, Truttmann MC, Bilate AM, Ingram JR, Ploegh HL (May 2015). "Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of '
                          'nonhomologous end joining". Nature Biotechnology. 33 (5): 538–42. doi:10.1038/nbt.3190. PMC\xa04618510. PMID\xa025798939.\n'
                          '\n'
                          '^ Ledford, Heidi (2016-03-07). "CRISPR: gene editing is just the beginning". Nature. 531 (7593): 156–159. Bibcode:2016Natur.531..156L. doi:10.1038/531156a. ISSN\xa0'
                          '0028-0836. PMID\xa026961639.\n'
                          '\n'
                          '^ a b c d e Science News Staff (December 17, 2015). "And Science\'s Breakthrough of the Year is …". news.sciencemag.org. Retrieved 2015-12-21.\n'
                          '\n'
                          '^ Ledford H (March 2016). "CRISPR: gene editing is just the beginning". Nature. 531 (7593): 156–9. Bibcode:2016Natur.531..156L. doi:10.1038/531156a. PMID\xa026961639.\n'
                          '\n'
                          '^ Dominguez AA, Lim WA, Qi LS (January 2016). "Beyond editing: repurposing CRISPR-Cas9 for precision genome regulation and interrogation". Nature Reviews Molecular Cell '
                          'Biology. 17 (1): 5–15. doi:10.1038/nrm.2015.2. PMC\xa04922510. PMID\xa026670017.\n'
                          '\n'
                          '^ Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, Heckl D, Ebert BL, Root DE, Doench JG, Zhang F (January 2014). "Genome-scale CRISPR-Cas9 knockout '
                          'screening in human cells". Science. 343 (6166): 84–7. Bibcode:2014Sci...343...84S. doi:10.1126/science.1247005. PMC\xa04089965. PMID\xa024336571.\n'
                          '\n'
                          '^ a b Zimmer C (2016-06-03). "Scientists Find Form of Crispr Gene Editing With New Capabilities". The New York Times. ISSN\xa00362-4331. Retrieved 2016-06-10.\n'
                          '\n'
                          '^ Basak J, Nithin C (2015). "Targeting Non-Coding RNAs in Plants with the CRISPR-Cas Technology is a Challenge yet Worth Accepting". Frontiers in Plant Science. 6: 1001. '
                          'doi:10.3389/fpls.2015.01001. PMC\xa04652605. PMID\xa026635829.\n'
                          '\n'
                          '^ van Erp PB, Bloomer G, Wilkinson R, Wiedenheft B (June 2015). "The history and market impact of CRISPR RNA-guided nucleases". Current Opinion in Virology. 12: 85–90. '
                          'doi:10.1016/j.coviro.2015.03.011. PMC\xa04470805. PMID\xa025914022.\n'
                          '\n'
                          '^ Maggio I, Gonçalves MA (May 2015). "Genome editing at the crossroads of delivery, specificity, and fidelity". Trends in Biotechnology. 33 (5): 280–91. '
                          'doi:10.1016/j.tibtech.2015.02.011. PMID\xa025819765.\n'
                          '\n'
                          '^ Rath D, Amlinger L, Rath A, Lundgren M (October 2015). "The CRISPR-Cas immune system: biology, mechanisms and applications". Biochimie. 117: 119–28. '
                          'doi:10.1016/j.biochi.2015.03.025. PMID\xa025868999.\n'
                          '\n'
                          '^ a b Freedman BS, Brooks CR, Lam AQ, Fu H, Morizane R, Agrawal V, et\xa0al. (October 2015). "Modelling kidney disease with CRISPR-mutant kidney organoids derived from '
                          'human pluripotent epiblast spheroids". Nature Communications. 6: 8715. Bibcode:2015NatCo...6E8715F. doi:10.1038/ncomms9715. PMC\xa04620584. PMID\xa026493500.\n'
                          '\n'
                          '^ Cruz NM, Song X, Czerniecki SM, Gulieva RE, Churchill AJ, Kim YK, et\xa0al. (November 2017). "Organoid cystogenesis reveals a critical role of microenvironment in human '
                          'polycystic kidney disease". Nature Materials. 16 (11): 1112–1119. Bibcode:2017NatMa..16.1112C. doi:10.1038/nmat4994. PMC\xa05936694. PMID\xa028967916.\n'
                          '\n'
                          '^ Kim YK, Refaeli I, Brooks CR, Jing P, Gulieva RE, Hughes MR, et\xa0al. (December 2017). "Gene-Edited Human Kidney Organoids Reveal Mechanisms of Disease in Podocyte '
                          'Development". Stem Cells. 35 (12): 2366–2378. doi:10.1002/stem.2707. PMC\xa05742857. PMID\xa028905451.\n'
                          '\n'
                          "^ Bellin M, Casini S, Davis RP, D'Aniello C, Haas J, Ward-van Oostwaard D, Tertoolen LG, Jung CB, Elliott DA, Welling A, Laugwitz KL, Moretti A, Mummery CL (December "
                          '2013). "Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome". The EMBO Journal. 32 (24): 3161–75. '
                          'doi:10.1038/emboj.2013.240. PMC\xa03981141. PMID\xa024213244.\n'
                          '\n'
                          '^ Akbari OS, Bellen HJ, Bier E, Bullock SL, Burt A, Church GM, et\xa0al. (August 2015). "BIOSAFETY. Safeguarding gene drive experiments in the laboratory". Science. 349 '
                          '(6251): 927–9. Bibcode:2015Sci...349..927A. doi:10.1126/science.aac7932. PMC\xa04692367. PMID\xa026229113.\n'
                          '\n'
                          '^ Caplan AL, Parent B, Shen M, Plunkett C (November 2015). "No time to waste--the ethical challenges created by CRISPR: CRISPR/Cas, being an efficient, simple, and cheap '
                          'technology to edit the genome of any organism, raises many ethical and regulatory issues beyond the use to manipulate human germ line cells". EMBO Reports. 16 (11): '
                          '1421–6. doi:10.15252/embr.201541337. PMC\xa04641494. PMID\xa026450575.\n'
                          '\n'
                          '^ Oye KA, Esvelt K, Appleton E, Catteruccia F, Church G, Kuiken T, et\xa0al. (August 2014). "Biotechnology. Regulating gene drives". Science. 345 (6197): 626–8. '
                          'Bibcode:2014Sci...345..626O. doi:10.1126/science.1254287. PMID\xa025035410.\n'
                          '\n'
                          '^ Cai L, Fisher AL, Huang H, Xie Z (December 2016). "CRISPR-mediated genome editing and human diseases". Genes & Diseases. 3 (4): 244–251. '
                          'doi:10.1016/j.gendis.2016.07.003.\n'
                          '\n'
                          '^ "Seven Diseases That CRISPR Technology Could Cure". Labiotech.eu. 2018-06-25. Retrieved 2018-08-22.\n'
                          '\n'
                          '^ Rana P, Marcus AD, Fan W (2018-01-21). "China, Unhampered by Rules, Races Ahead in Gene-Editing Trials". Wall Street Journal. Retrieved 2018-08-22.\n'
                          '\n'
                          '^ Mullin E. "The first human CRISPR study in the U.S. could begin at any time". MIT Technology Review. Retrieved 2018-08-22.\n'
                          '\n'
                          '^ Xie F, Ye L, Chang JC, Beyer AI, Wang J, Muench MO, Kan YW (September 2014). "Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using '
                          'CRISPR/Cas9 and piggyBac". Genome Research. 24 (9): 1526–33. doi:10.1101/gr.173427.114. PMC\xa04158758. PMID\xa025096406.\n'
                          '\n'
                          '^ Ledford H (2016-10-12). "CRISPR deployed to combat sickle-cell anaemia". Nature. doi:10.1038/nature.2016.20782.\n'
                          '\n'
                          '^ "CRISPR "One Shot Cell Therapy for Hemophilia Developed | GEN". GEN. Retrieved 2018-08-22.\n'
                          '\n'
                          '^ Marangi M, Pistritto G (2018-04-20). "Innovative Therapeutic Strategies for Cystic Fibrosis: Moving Forward to CRISPR Technique". Frontiers in Pharmacology. 9: 396. '
                          'doi:10.3389/fphar.2018.00396. PMC\xa05920621. PMID\xa029731717.\n'
                          '\n'
                          '^ "New CRISPR method efficiently corrects Duchenne muscular dystrophy defect in heart tissue". ScienceDaily. Retrieved 2018-08-22.\n'
                          '\n'
                          '^ Eisenstein M (May 2018). "CRISPR takes on Huntington\'s disease". Nature. 557 (7707): S42–S43. doi:10.1038/d41586-018-05177-y. PMID\xa029844549.\n'
                          '\n'
                          '^ Dabrowska M, Juzwa W, Krzyzosiak WJ, Olejniczak M (2018). "Precise Excision of the CAG Tract from the Huntingtin Gene by Cas9 Nickases". Frontiers in Neuroscience. 12: '
                          '75. doi:10.3389/fnins.2018.00075. PMC\xa05834764. PMID\xa029535594.\n'
                          '\n'
                          '^ King A (March 2018). "A CRISPR edit for heart disease". Nature. 555 (7695): S23–S25. doi:10.1038/d41586-018-02482-4. PMID\xa029517035.\n'
                          '\n'
                          '^ Gomaa AA, Klumpe HE, Luo ML, Selle K, Barrangou R, Beisel CL (January 2014). "Programmable removal of bacterial strains by use of genome-targeting CRISPR-Cas systems". '
                          'MBio. 5 (1): e00928–13. doi:10.1128/mBio.00928-13. PMC\xa03903277. PMID\xa024473129.\n'
                          '\n'
                          '^ Citorik RJ, Mimee M, Lu TK (November 2014). "Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases". Nature Biotechnology. 32 (11): 1141–5. '
                          'doi:10.1038/nbt.3011. hdl:1721.1/100834. PMC\xa04237163. PMID\xa025240928.\n'
                          '\n'
                          '^ a b Gholizadeh P, Aghazadeh M, Asgharzadeh M, Kafil HS (October 2017). "Suppressing the CRISPR/Cas adaptive immune system in bacterial infections". European Journal of '
                          'Clinical Microbiology & Infectious Diseases. 36 (11): 2043–2051. doi:10.1007/s10096-017-3036-2. PMID\xa028601970.CS1 maint: extra punctuation (link)\n'
                          '\n'
                          '^ van Diemen FR, Kruse EM, Hooykaas MJ, Bruggeling CE, Schürch AC, van Ham PM, Imhof SM, Nijhuis M, Wiertz EJ, Lebbink RJ (2016). "CRISPR/Cas9-Mediated Genome Editing of '
                          'Herpesviruses Limits Productive and Latent Infections". PLoS Pathogens. 12 (6): e1005701. doi:10.1371/journal.ppat.1005701. PMC\xa04928872. PMID\xa027362483. Cite uses '
                          'deprecated parameter |laysource= (help); Unknown parameter |laysummary= ignored (|lay-url= suggested) (help)\n'
                          '\n'
                          '^ Liu Y, Zhan Y, Chen Z, He A, Li J, Wu H, et\xa0al. (September 2016). "Directing cellular information flow via CRISPR signal conductors". Nature Methods. 13 (11): '
                          '938–944. doi:10.1038/nmeth.3994. PMID\xa027595406.\n'
                          '\n'
                          '^ Mullin E. "Using CRISPR on pigs could make their organs safer for human transplant". MIT Technology Review. Retrieved 2017-09-09.\n'
                          '\n'
                          '^ Abrahimi P, Chang WG, Kluger MS, Qyang Y, Tellides G, Saltzman WM, Pober JS (July 2015). "Efficient gene disruption in cultured primary human endothelial cells by '
                          'CRISPR/Cas9". Circulation Research. 117 (2): 121–8. doi:10.1161/CIRCRESAHA.117.306290. PMC\xa04490936. PMID\xa025940550.\n'
                          '\n'
                          '^ Khan FA, Pandupuspitasari NS, Chun-Jie H, Ao Z, Jamal M, Zohaib A, Khan FA, Hakim MR, ShuJun Z (August 2016). "CRISPR/Cas9 therapeutics: a cure for cancer and other '
                          'genetic diseases". Oncotarget. 7 (32): 52541–52552. doi:10.18632/oncotarget.9646. PMC\xa05239572. PMID\xa027250031.\n'
                          '\n'
                          '^ Le Page M (7 June 2017). "Boom in human gene editing as 20 CRISPR trials gear up". New Scientist.\n'
                          '\n'
                          '^ Reardon S (2016). "First CRISPR clinical trial gets green light from US panel". Nature. doi:10.1038/nature.2016.20137.\n'
                          '\n'
                          '^ "CRISPR Therapeutics Plans First CRISPR Clinical Trial in Europe for 2018". Labiotech.eu. 2017-12-13. Retrieved 2018-08-22.\n'
                          '\n'
                          '^ "CRISPR Beta-Thalassemia Treatment Approved for Clinical Trial in Europe". Genome Magazine. Retrieved 2018-08-22.\n'
                          '\n'
                          '^ Yong E (2015-11-25). "The Revolutionary Gene-Editing Technique That Reveals Cancer\'s Weaknesses". The Atlantic. Retrieved 2016-02-21.\n'
                          '\n'
                          '^ Gu W, Crawford ED, O\'Donovan BD, Wilson MR, Chow ED, Retallack H, DeRisi JL (March 2016). "Depletion of Abundant Sequences by Hybridization (DASH): using Cas9 to remove '
                          'unwanted high-abundance species in sequencing libraries and molecular counting applications". Genome Biology. 17: 41. doi:10.1186/s13059-016-0904-5. PMC\xa04778327. '
                          'PMID\xa026944702.\n'
                          '\n'
                          '^ Zuo E, Huo X, Yao X, Hu X, Sun Y, Yin J, et\xa0al. (2017). "CRISPR/Cas9-mediated targeted chromosome elimination". Genome Biology. 18 (1): 224. '
                          'doi:10.1186/s13059-017-1354-4. PMC\xa05701507. PMID\xa029178945. Unknown parameter |lay-summary= ignored (|lay-url= suggested) (help)\n'
                          '\n'
                          '^ Javed MR, Sadaf M, Ahmed T, Jamil A, Nawaz M, Abbas H, Ijaz A (August 2018). "CRISPR-Cas System: History and Prospects as a Genome Editing Tool in Microorganisms". '
                          'review. Current Microbiology. doi:10.1007/s00284-018-1547-4. PMID\xa030078067.\n'
                          '\n'
                          '^ Giersch RM, Finnigan GC (December 2017). "Yeast Still a Beast: Diverse Applications of CRISPR/Cas Editing Technology in S. cerevisiae". The Yale Journal of Biology and '
                          'Medicine. 90 (4): 643–651. PMC\xa05733842. PMID\xa029259528.\n'
                          '\n'
                          '^ Raschmanová H, Weninger A, Glieder A, Kovar K, Vogl T (2018). "Implementing CRISPR-Cas technologies in conventional and non-conventional yeasts: Current state and future '
                          'prospects". review. Biotechnology Advances. 36 (3): 641–665. doi:10.1016/j.biotechadv.2018.01.006. PMID\xa029331410.\n'
                          '\n'
                          '^ a b Ma D, Liu F (December 2015). "Genome Editing and Its Applications in Model Organisms". review. Genomics, Proteomics & Bioinformatics. 13 (6): 336–44. '
                          'doi:10.1016/j.gpb.2015.12.001. PMC\xa04747648. PMID\xa026762955.\n'
                          '\n'
                          '^ Khurshid H, Jan SA, Shinwari ZK, Jamal M, Shah SH (2018). "An Era of CRISPR/ Cas9 Mediated Plant Genome Editing". review. Current Issues in Molecular Biology. 26: 47–54. '
                          'doi:10.21775/cimb.026.047. PMID\xa028879855.\n'
                          '\n'
                          '^ Simone BW, Martínez-Gálvez G, WareJoncas Z, Ekker SC (August 2018). "Fishing for understanding: Unlocking the zebrafish gene editor\'s toolbox". review. Methods. '
                          'doi:10.1016/j.ymeth.2018.07.012. PMID\xa030076892.\n'
                          '\n'
                          '^ Singh P, Schimenti JC, Bolcun-Filas E (January 2015). "A mouse geneticist\'s practical guide to CRISPR applications". review. Genetics. 199 (1): 1–15. '
                          'doi:10.1534/genetics.114.169771. PMC\xa04286675. PMID\xa025271304.\n'
                          '\n'
                          '^ Soni D, Wang DM, Regmi SC, Mittal M, Vogel SM, Schlüter D, Tiruppathi C (May 2018). "Deubiquitinase function of A20 maintains and repairs endothelial barrier after lung '
                          'vascular injury". Cell Death Discovery. 4 (60). doi:10.1038/s41420-018-0056-3.\n'
                          '\n'
                          '^ Gao X, Tao Y, Lamas V, Huang M, Yeh WH, Pan B, et\xa0al. (December 2017). "Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents" '
                          '(Submitted manuscript). Nature. 553 (7687): 217–221. Bibcode:2018Natur.553..217G. doi:10.1038/nature25164. PMC\xa05784267. PMID\xa029258297.\n'
                          '\n'
                          '^ Kadam US, Shelake RM, Chavhan RL, Suprasanna P (October 2018). "Concerns regarding \'off-target\' activity of genome editing endonucleases". review. Plant Physiology and '
                          'Biochemistry. 131: 22–30. doi:10.1016/j.plaphy.2018.03.027. PMID\xa029653762.\n'
                          '\n'
                          '^ Kimberland ML, Hou W, Alfonso-Pecchio A, Wilson S, Rao Y, Zhang S, Lu Q (August 2018). "Strategies for controlling CRISPR/Cas9 off-target effects and biological '
                          'variations in mammalian genome editing experiments". review. Journal of Biotechnology. 284: 91–101. doi:10.1016/j.jbiotec.2018.08.007. PMID\xa030142414.\n'
                          '\n'
                          '^ "Who Owns the Biggest Biotech Discovery of the Century? There\'s a bitter fight over the patents for CRISPR, a breakthrough new form of DNA editing". MIT Technology '
                          'Review. Retrieved 25 February 2015. CRISPR Patents Spark Fight to Control Genome Editing\n'
                          '\n'
                          '^ Fye S. "Genetic Rough Draft: Editas and CRISPR". The Atlas Business Journal. Retrieved 19 January 2016.\n'
                          '\n'
                          '^ Pollack A (15 February 2017). "Harvard and M.I.T. Scientists Win Gene-Editing Patent Fight". The New York Times.\n'
                          '\n'
                          '^ Akst J (February 15, 2017). "Broad Wins CRISPR Patent Interference Case". The Scientist Magazine.\n'
                          '\n'
                          '^ Noonan KE (February 16, 2017). "PTAB Decides CRISPR Interference in Favor of Broad Institute -- Their Reasoning". Patent Docs.\n'
                          '\n'
                          '^ Potenza A (April 13, 2017). "UC Berkeley challenges decision that CRISPR patents belong to Broad Institute 3 comments The legal fight will likely continue for months or '
                          'even years". The Verge. Retrieved 22 September 2017.\n'
                          '\n'
                          '^ Buhr S (July 26, 2017). "The CRISPR patent battle is back on as UC Berkeley files an appeal". TechCrunch. Retrieved 22 September 2017.\n'
                          '\n'
                          '^ "CRISPR Madness". GEN.\n'
                          '\n'
                          '^ Staff (1 April 2015). "News: Products & Services". Genetic Engineering & Biotechnology News (Paper). 35 (7): 8.\n'
                          '\n'
                          '^ a b Philippidis A (August 7, 2017). "MilliporeSigma to Be Granted European Patent for CRISPR Technology". Genetic Engineering & Biotechology News. Retrieved 22 September '
                          '2017.\n'
                          '\n'
                          '^ Akst J (March 24, 2017). "UC Berkeley Receives CRISPR Patent in Europe". The Scientist. Retrieved 22 September 2017.\n'
                          '\n'
                          '^ Cohen J (4 August 2017). "CRISPR patent battle in Europe takes a \'wild\' twist with surprising player". Science. doi:10.1126/science.aan7211.\n'
                          '\n'
                          '^ "CRISPR Cas9 Genome Editing Market Worth $5.3 Billion by 2025". PRWeb. Retrieved 2018-11-30.\n'
                          '\n'
                          '^ Regalado A (March 5, 2015). "Engineering the Perfect Baby". MIT Technology Review.\n'
                          '\n'
                          '^ Baltimore D, Berg P, Botchan M, Carroll D, Charo RA, Church G, Corn JE, Daley GQ, Doudna JA, Fenner M, Greely HT, Jinek M, Martin GS, Penhoet E, Puck J, Sternberg SH, '
                          'Weissman JS, Yamamoto KR (April 2015). "Biotechnology. A prudent path forward for genomic engineering and germline gene modification". Science. 348 (6230): 36–8. '
                          'Bibcode:2015Sci...348...36B. doi:10.1126/science.aab1028. PMC\xa04394183. PMID\xa025791083.\n'
                          '\n'
                          '^ Lanphier E, Urnov F, Haecker SE, Werner M, Smolenski J (March 2015). "Don\'t edit the human germ line". Nature. 519 (7544): 410–1. Bibcode:2015Natur.519..410L. '
                          'doi:10.1038/519410a. PMID\xa025810189.\n'
                          '\n'
                          '^ Wade N (19 March 2015). "Scientists Seek Ban on Method of Editing the Human Genome". The New York Times. Retrieved 20 March 2015. The biologists writing in Science '
                          'support continuing laboratory research with the technique, and few if any scientists believe it is ready for clinical use.\n'
                          '\n'
                          '^ Liang P, Xu Y, Zhang X, Ding C, Huang R, Zhang Z, Lv J, Xie X, Chen Y, Li Y, Sun Y, Bai Y, Songyang Z, Ma W, Zhou C, Huang J (May 2015). "CRISPR/Cas9-mediated gene '
                          'editing in human tripronuclear zygotes". Protein & Cell. 6 (5): 363–72. doi:10.1007/s13238-015-0153-5. PMC\xa04417674. PMID\xa025894090.\n'
                          '\n'
                          '^ Kolata G (23 April 2015). "Chinese Scientists Edit Genes of Human Embryos, Raising Concerns". The New York Times. Retrieved 24 April 2015.\n'
                          '\n'
                          '^ a b Cyranoski D, Reardon S (2015). "Chinese scientists genetically modify human embryos". Nature. doi:10.1038/nature.2015.17378.\n'
                          '\n'
                          '^ Regalado A (2016-05-08). "Chinese Researchers Experiment with Making HIV-Proof Embryos". MIT Technology Review. Retrieved 2016-06-10.\n'
                          '\n'
                          '^ "International Summit on Gene Editing". National Academies of Sciences, Engineering, and Medicine. 3 December 2015. Retrieved 3 December 2015.\n'
                          '\n'
                          '^ Begley S (28 November 2018). "Amid uproar, Chinese scientist defends creating gene-edited babies". STAT.\n'
                          '\n'
                          '^ Callaway E (February 2016). "UK scientists gain licence to edit genes in human embryos". Nature. 530 (7588): 18. Bibcode:2016Natur.530...18C. '
                          'doi:10.1038/nature.2016.19270. PMID\xa026842037.\n'
                          '\n'
                          '^ McHughen A, Smyth S (January 2008). "US regulatory system for genetically modified [genetically modified organism (GMO), rDNA or transgenic] crop cultivars". Plant '
                          'Biotechnology Journal. 6 (1): 2–12. doi:10.1111/j.1467-7652.2007.00300.x. PMID\xa017956539.\n'
                          '\n'
                          '^ USDA. "Re: Request to confirm" (PDF).\n'
                          '\n'
                          '^ Waltz E (2016). "Gene-edited CRISPR mushroom escapes US regulation". Nature. 532 (7599): 293. Bibcode:2016Natur.532..293W. doi:10.1038/nature.2016.19754. PMID\xa0'
                          '27111611.\n'
                          '\n'
                          '^ Ledford H (April 2016). "Gene-editing surges as US rethinks regulations". Nature. 532 (7598): 158–9. Bibcode:2016Natur.532..158L. doi:10.1038/532158a. PMID\xa027075074.\n'
                          '\n'
                          '^ "The FDA Is Cracking Down On Rogue Genetic Engineers", Kristen V. Brown. Gizmodo. February 1, 2017. Retrieved 5 feb 2017\n'
                          '\n'
                          '^ "Guidance for Industry #187 / Regulation of Intentionally Altered Genomic DNA in Animals" (PDF).\n'
                          '\n'
                          '^ Cyranoski D (2017). "China\'s embrace of embryo selection raises thorny questions". Nature. 548 (7667): 272–274. Bibcode:2017Natur.548..272C. doi:10.1038/548272a. '
                          'PMID\xa028816265.\n'
                          '\n'
                          '^ Peng Y (2016). "The morality and ethics governing CRISPR-Cas9 patents in China". Nature Biotechnology. 34 (6): 616–8. doi:10.1038/nbt.3590. PMID\xa027281418.\n'
                          '\n'
                          '^ Rana P, Marcus AD, Fan W (2018-01-21). "China, Unhampered by Rules, Races Ahead in Gene-Editing Trials". Wall Street Journal. ISSN\xa00099-9660. Retrieved 2018-01-23.\n'
                          '\n'
                          '^ Talbot D (2016). "Precise Gene Editing in Plants/ 10 Breakthrough Technologies 2016". MIT Technology review. Massachusetts Institute of Technology. Retrieved 18 March '
                          '2016.\n'
                          '\n'
                          '^ Larson C, Schaffer A (2014). "Genome Editing/ 10 Breakthrough Technologies 2014". Massachusetts Institute of Technology. Retrieved 18 March 2016.\n'
                          '\n'
                          '^ 良艮創意, 很好設計, 李維宗設計. "Tang Prize Laureates". www.tang-prize.org. Retrieved 2018-08-05.',
                  'subsections': []}]}

====================================================================================================
History Section

NO HISTORY SECTION